Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Ionis Pharmaceuticals, Inc. Common Stock

IONS

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Last trade $26.79
Day change -$1.22 (-4.36%)
Day range $26.74 – $28.49
Volume 1,835,081
Market cap $4.66B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.66B
Price / earnings
—
Price / book
11.85×
Price / sales
4.86×
EV / sales
5.93×
EV / EBITDA
-10.33×

Profitability

Earnings per share
-$3.28
Return on assets
-18.76%
Return on equity
-138.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.36×
Current ratio
5.43×
Quick ratio
5.36×
Cash ratio
0.68×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$616.26M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IONS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$242.72M$267.95M$246.09M$203.33M$156.72M$452.05M$131.61M$226.58M
Cost of revenue$3.32M$2.74M$2.98M$7.96M$2.34M$4.15M$1.46M$3.83M
Gross profit$239.4M$265.21M$243.11M$195.37M$154.38M$447.9M$130.15M$222.75M
Selling, general and administrative$154.22M$150.4M$150.36M$130.19M$96.81M$90.62M$76.25M$88.08M
Research and development$215.88M$217.11M$210.17M$279.65M$217.75M$217.46M$200.76M$245.49M
Total operating expenses$370.1M$367.5M$360.53M$409.83M$314.56M$308.08M$277.01M$333.57M
Operating income-$130.7M-$102.29M-$117.42M-$214.46M-$160.18M$139.82M-$146.86M-$110.82M
Interest expense-$8.76M-$22.12M-$22.5M-$22.69M-$22.16M-$22.76M-$22.93M-$22.86M
Income before taxes-$110.11M-$113.38M-$92.31M-$227.92M-$128.39M$123.53M-$146.82M-$107.04M
Income taxes-$141K$1.26M$218K$1.48M$213K-$20K$116K-$2.69M
Net income-$109.97M-$114.65M-$92.53M-$229.39M-$128.61M$123.55M-$146.94M-$104.35M
Net income attributable to common shareholders-$109.97M-$114.65M-$92.53M-$229.39M-$128.61M$123.55M-$146.94M-$104.35M
EBITDA-$126.37M-$98.16M-$113.46M-$213M-$157.31M$142.68M-$144.05M-$110.46M
Basic earnings per share-$0.66-$0.69-$0.56-$1.41-$0.80$0.78-$0.93-$0.66
Diluted earnings per share-$0.66-$0.69-$0.56-$1.65-$0.80$0.70-$0.93-$0.66

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Ionis: 3 Key Takeaways for Long-Term Investors

Ionis lowered its 2026 TRYNGOLZA revenue guidance to ~$50 million due to a slower-than-anticipated launch ramp, while DAWNZERA showed strong momentum with 40% quarterly sales growth to $37 million. However, Phase III clinical trial setbacks in partnered programs forced management to delay its positive cash flow target from 2028 to 2029, though the company maintains a $1.9 billion cash position.

Zacks Investment Research

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

Ionis Pharmaceuticals is expected to report Q3 2026 earnings with a year-over-year EPS decline of 63.9% to a loss of $1.00 per share, though revenues are projected to rise 14% to $178.93 million. With a negative Earnings ESP of -26.63% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has a strong history of beating estimates in the last four quarters.

Zacks Investment Research

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Novartis reported Q3 2026 core EPS of $2.46, beating estimates by 9.3%, with 9% year-over-year growth. However, revenues of $14.52 billion missed consensus by 0.2%. Strong sales from priority drugs like Kisqali, Kesimpta, and Scemblix offset generic competition. The company raised its core operating income guidance but faced pipeline setbacks with del-desiran and pelacarsen failing to meet primary endpoints.

GlobeNewswire Inc.

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.